OneDrug

OneDrug Our point-of-care devices will rapidly identify patients at-risk of adverse drug effects.

New Study Confirms DPYD Genotype-Based Dosing Reduces Fluoropyrimidine Toxicity Risk 💊🧬 Genotype-guided dosing helps var...
09/01/2025

New Study Confirms DPYD Genotype-Based Dosing Reduces Fluoropyrimidine Toxicity Risk 💊🧬

Genotype-guided dosing helps variant carriers match wild-type patients in safety—supporting updated guidelines!

Aims Several international guidelines recommend DPYD genotype-based dosing in patients treated with fluoropyrimidines. This study evaluates the incidences of severe fluoropyrimidine-related toxicity...

New Study Shows Modest Impact but High Engagement with Pharmacogenomics in African American Inpatients: ACCOuNT Trial Re...
08/25/2025

New Study Shows Modest Impact but High Engagement with Pharmacogenomics in African American Inpatients: ACCOuNT Trial Results Reveal Frequent Use to Affirm Prescribing Decisions

Pharmacogenomics implementation efforts have increased over the last decade, but no published prospective pharmacogenomics trials have formally evaluated utility in underrepresented populations. We p...

Addressing inflammation-mediated interactions with antibiotics in critically ill patients is essential for achieving opt...
08/18/2025

Addressing inflammation-mediated interactions with antibiotics in critically ill patients is essential for achieving optimal therapeutic efficacy and safety.

Due to extensive pathophysiological changes in critically ill patients, standard dosing of antibiotics may lead to inadequate drug exposure. This is concerning, as insufficient plasma drug concentrat...

New Study Reveals Sub-Saharan CYP2D6 Variants May Alter Risperidone Metabolism, Highlighting Need for Ancestry-Informed ...
08/11/2025

New Study Reveals Sub-Saharan CYP2D6 Variants May Alter Risperidone Metabolism, Highlighting Need for Ancestry-Informed Dosing

CYP2D6 alleles with low frequency in Eurocentrically biased study populations are often excluded from pharmacogenetic investigation and consequently may have misassigned activity values. This health ...

New Biomarker Test Helps Identify Hidden CYP2D6 Poor Metabolizers, Reducing Need for Broad Genotyping
08/04/2025

New Biomarker Test Helps Identify Hidden CYP2D6 Poor Metabolizers, Reducing Need for Broad Genotyping

Cytochrome P450 2D6 (CYP2D6) is involved in the metabolism of 20–25% of commonly used clinical drugs. Between 5 and 10% of Caucasians are homozygous carriers of variant alleles encoding no CYP2D6 enz...

🔬🧠 Findings suggest certain PD gene polymorphisms predict remission, offering hope for personalized treatment approaches...
07/28/2025

🔬🧠 Findings suggest certain PD gene polymorphisms predict remission, offering hope for personalized treatment approaches.


We examined the association of selected candidate pharmacodynamic (PD) genes in MDD with treatment outcomes, defined according to remission thresholds for Hamilton Depression Rating Scale (HDRS) with 6- and 17- items. To this end, we recruited 158 individuals living with MDD followed in an academic....

CPIC Leads Global Pharmacogenomics Adoption with 10K+ Citations, 1.4M Views, and Growing EHR Integration
07/21/2025

CPIC Leads Global Pharmacogenomics Adoption with 10K+ Citations, 1.4M Views, and Growing EHR Integration

The Clinical Pharmacogenetics Implementation Consortium (CPIC) has advanced clinical pharmacogenomics since 2009 by developing freely available, evidence-based gene/drug guidelines. Covering 34 genes...

Pharmacogenetic Testing Shows Promise But Implementation Challenges Remain in Gynecologic Surgery Pain Management
07/15/2025

Pharmacogenetic Testing Shows Promise But Implementation Challenges Remain in Gynecologic Surgery Pain Management

pective, open-label pilot study was conducted in gynecologic patients undergoing abdominal surgery. Participants received multigene PGx testing and were randomized to the PGx-guided group where results were returned to the electronic health record with pharmacist genotype-guided postoperative analge...

ABCC4 Gene Variant Found to Indirectly Lower 5′-DFUR AUC in Capecitabine Treatment via TP Upregulation
07/07/2025

ABCC4 Gene Variant Found to Indirectly Lower 5′-DFUR AUC in Capecitabine Treatment via TP Upregulation

Aims Capecitabine converts to 5-fluorouracil (5-FU) in 3 steps. We previous demonstrated a significant association between area under the plasma concentration–time curve (AUC) of a metabolite 5′-deo...

Address

Toronto, ON

Opening Hours

Monday 9am - 5pm
Tuesday 9am - 5pm
Wednesday 9am - 5pm
Thursday 9am - 5pm
Friday 9am - 5pm

Website

https://linktr.ee/onedrug

Alerts

Be the first to know and let us send you an email when OneDrug posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to OneDrug:

Share